Continuous under-skin apomorphine for people with advanced Parkinson's at the end of life
Official title: Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life
Run by Centre Hospitalier Régional d'Orléans · NCT07257861 · Data updated 2026-11-12
This project will try continuous under‑skin apomorphine pumps to prevent dopaminergic withdrawal and ease symptoms for people with advanced Parkinson's who can no longer take oral medications near the end of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Centre Hospitalier Régional d'Orléans Academic / other |
| Locations | 1 site (Crest) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | February 2027 |
| Study ends | February 2027 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT07257861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults with advanced Parkinson's disease (Hoehn & Yahr OFF = 5) who have an indication for an apomorphine pump, have lost oral intake, are under palliative home care, and can consent or have a trusted proxy.
✕Probably not a fit
People already using an apomorphine pump, those who refuse pump treatment, or those who can still take oral antiparkinsonian medications are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will follow adults with advanced Parkinson's who have an indication for an apomorphine pump and have lost oral intake, collecting questionnaire data from patients or trusted proxies. Patients receiving home palliative care who are started on continuous subcutaneous apomorphine will be described and outcomes such as dopaminergic withdrawal syndrome, symptom control, comfort, and place of death will be recorded. The protocol excludes those already using an apomorphine pump, people who oppose pump introduction, and legally protected or otherwise ineligible persons. Collected data will be used to characterize real‑world use of apomorphine pumps in end‑of‑life Parkinson's care and to inform best practices for symptom management.
Why it matters
Potential benefit: If successful, this approach could reduce severe dopaminergic withdrawal, improve comfort in the final days, and help more patients remain at home for end‑of‑life care.
How similar studies have gone: Retrospective work from Rennes and case series suggest continuous apomorphine can prevent withdrawal syndromes and improve comfort, but prospective or randomized evidence in end‑of‑life Parkinson's patients is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Person (or trusted person/relative if patient is unable) who has agreed to participate in the study 2. Patient of legal age 3. Advanced Parkinson's disease with apomorphine pump indication 4. Use of HH for palliative reasons 5. Loss of orality (discontinuation of oral treatments) 6. Hoehn \&Yahr score in OFF = 5 (bilateral and axial symptoms in the absence of levodopa) Exclusion Criteria: 1. Apomorphine pump already in use 2. Opposition to the introduction of an apomorphine pump 3. Protected person (under guardianship or curatorship) 4. Person under court protection 5. Persons deprived of liberty 6. Persons not affiliated to a social security scheme 7. Pregnant or breast-feeding woman
Where it's running
-
Had Crest
Crest, France Recruiting
Study contacts
- Study coordinator: Marc VERIN, MD PhD
- Email: marc.verin@chu-orleans.fr
- Phone: 02 38 51 48 86
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.